Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
The purpose of the study is to determine if an investigational vaccine with a single
 component develops an immune response that is similar to the equivalent investigational
 vaccine with four components to reduce cervical disease.
Inclusion Criteria:

 -  Female with an intact uterus with lifetime history of 0-4 sexual partners

 Exclusion Criteria:

 -  Prior Human Papillomavirus Vaccine (HPV) vaccination;

 -  Prior abnormal paps;

 -  Prior history of genital warts